PROM1 and brain neoplasm: For example, CD133-specific chimeric antigen receptor (CAR)-T cells developed by Vora et al. have demonstrated preclinical success in targeting self-renewing and chemoradioresistant CD133+ brain tumor-initiating cells [95].